Risk of overall death among patients with RA, according to known predictors and mannose-binding lectin. Univariate Cox proportional-hazards regression analysis.
| Variables | N | HR | 95% CI | p |
|---|---|---|---|---|
| Duration of disease (decade) | 229 | 1.3 | 1.1–1.5 | 0.004 |
| Erosive disease | 229 | 1.6 | 1.0–2.8 | 0.07 |
| HAQ score | 224 | 1.5 | 1.1–2.1 | 0.007 |
| Extraarticular manifestations | 219 | 2.2 | 1.3–3.7 | 0.003 |
| IgM RF-positive | 224 | 2.1 | 1.1–3.9 | 0.03 |
| CRP > 100 mg/dl | 221 | 2.2 | 1.3–3.6 | 0.002 |
| HLA-DR1/HLA-DR4 | 224 | 1.6 | 0.9–2.9 | 0.09 |
| Smoking | 207 | 1.3 | 0.8–2.1 | 0.25 |
| Nutrition below normal | 216 | 2.6 | 1.5–4.4 | < 0.001 |
| Nutrition above normal | 216 | 0.9 | 0.5–1.5 | 0.61 |
| Hypertension | 227 | 0.9 | 0.5–1.5 | 0.73 |
| Diabetes | 229 | 1.8 | 0.9–3.5 | 0.11 |
| MTX treatment | 229 | 0.6 | 0.3–0.9 | 0.02 |
| Anti-TNF-α drugs | 229 | 0.2 | 0.1–0.6 | 0.004 |
| MBL2 genotype A/A* | 229 | 1.7 | 1.1–2.8 | 0.02 |
| MBL2 genotype YA/YA** | 215 | 1.4 | 0.9–2.2 | 0.143 |
| Serum MBL | 209 | 1.2 | 1.0–1.3 | 0.02 |
↵* Comparing MBL2 genotype A/A with A/O + O/O.
↵** Comparing MBL2 genotype YA/YA with YA/XA + XA/XA + YA/O+ XA/O + O/O. HR: hazard ratio; HAQ: Health Assessment Questionnaire; RF: rheumatoid factor; CRP: C-reactive protein; HLA: human leukocyte antigen; MBL: mannose-binding lectin; MTX: methotrexate; TNF-α: tumor necrosis factor-α.